Puska, P., A. Nissinen, J. Tuomilehto, J. T. Salonen, K. Koskela, A. McAlister, T. E. Kottke, N. Maccoby, and J. W. Farquhar. 1985. The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Annual Review of Public Health 6:147-193.

Ravishankar, N., P. Gubbins, R. J. Cooley, K. Leach-Kemon, C. M. Michaud, D. T. Jamison, and C. J. Murray. 2009. Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet 373(9681):2113-2124.

Redekop, W. K., E. Orlewska, P. Maciejewski, F. F. Rutten, and L. W. Niessen. 2008. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: An analysis of the Europa Study including 1251 Polish patients. Pharmacoeconomics 26(10):861-877.

Robberstad, B., Y. Hemed, O. F. Norheim. 2007. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a Sub-Saharan African country—the case of Tanzania. Cost Effectiveness and Resource Allocation 5:3.

Rodriguez, A., F. Boullon, N. Perez-Balino, C. Paviotti, M. I. Liprandi, and I. F. Palacios. 1993. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): In-hospital results and 1-year follow-up. Eraci group. Journal of the American College of Cardiology 22(4):1060-1067.

Rossouw, J. E., P. L. Jooste, D. O. Chalton, E. R. Jordaan, M. L. Langenhoven, P. C. Jordaan, M. Steyn, A. S. Swanepoel, and L. J. Rossouw. 1993. Community-based intervention: The coronary risk factor study (CORIS). International Journal of Epidemiology 22(3):428-438.

Roux, L., M. Pratt, T. O. Tengs, M. M. Yore, T. L. Yanagawa, J. Van Den Bos, C. Rutt, R. C. Brownson, K. E. Powell, G. Heath, H. W. Kohl, 3rd, S. Teutsch, J. Cawley, I. M. Lee, L. West, and D. M. Buchner. 2008. Cost-effectiveness of community-based physical activity interventions. American Journal of Preventive Medicine 35(6):578-588.

Rubinstein, A., S. Garcia Marti, A. Souto, D. Ferrante, and F. Augustovski. 2009. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Effectiveness and Resource Allocation 7(1):10.

Salvetti, X. M., J. A. Oliveira, D. M. Servantes, and A. A. Vincenzo de Paola. 2008. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease. Clinical Rehabilitation 22(10-11):987-996.

Schooler, C., J. W. Farquhar, S. P. Fortmann, and J. A. Flora. 1997. Synthesis of findings and issues from community prevention trials. Annals of Epidemiology 7(Suppl 1):S54-S68.

Schwappach, D., T. Boluarte, and M. Suhrcke. 2007. The economics of primary prevention of cardiovascular disease—a systematic review of economic evaluations. Cost-Effectiveness and Resource Allocation 5(1):5.

Shafiq, N., S. Malhotra, P. Pandhi, N. Sharma, A. Bhalla, and A. Grover. 2006. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins—enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacology 78(3):136-143.

Shibuya, K., C. Ciecierski, E. Guindon, D. W. Bettcher, D. B. Evans, and C. J. L. Murray. 2003. WHO Framework Convention on Tobacco Control: Development of an evidence based global public health treaty. British Medical Journal 327(7407):154-157.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement